Kolexia
Chatelut Etienne
Pharmacien
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
195 Activités
1.1 K Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Métastase tumorale Tumeurs colorectales Tumeurs du sein Néphrocarcinome Tumeurs embryonnaires et germinales Infections à VIH Thrombopénie Récidive tumorale locale

Industries

Pierre Fabre
1 collaboration(s)
Dernière en 2020
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Apport de la pharmacocinétique de population à l’analyse des données sanguines et d’imagerie dans la radiothérapie interne vectorisée par Lutathéra®
10e Journées Francophones de Médecine nucléaire - Biarritz   01 mars 2024
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
British journal of cancer   25 janvier 2024
Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing.
Clinical chemistry and laboratory medicine   11 janvier 2024
Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day.
Bulletin du cancer   10 octobre 2023
Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer.
Cancer chemotherapy and pharmacology   03 octobre 2023
Investigating the clinical impact of dose-banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study.
British journal of clinical pharmacology   20 mars 2023
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.
Cancer chemotherapy and pharmacology   09 mars 2023
Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences   05 mars 2023
Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice.
Clinical pharmacokinetics   11 janvier 2023
Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs.
ESMO open   03 janvier 2023